Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe

20years of experience

Research output: Contribution to journalArticle

143 Citations (Scopus)

Abstract

The susceptibilities of 824 Bacteroides fragilis group isolates against nine antibiotics were evaluated in a Europe-wide study involving 13 countries. Species determination, by different methods, was carried out on all but one isolate. Resistance rates were evaluated according to species and geographical areas via CLSI and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints. The present data were compared with those obtained 10 and 20years ago at a European level. High-level resistance (MIC ≥64mg/L) to ampicillin was observed in 44.5% of the strains, which is a significant increase relative to 20years ago (16%). Piperacillin/tazobactam was more active than amoxicillin/clavulanic acid (3.1% and 10.4% resistance, respectively), again with a resistance increase relative to earlier studies. Dramatic increases in resistance were observed for cefoxitin, clindamycin and moxifloxacin, with rates of 17.2%, 32.4% and 13.6%, respectively. The lowest resistances were found for imipenem, metronidazole and tigecycline (1.2%,

Original languageEnglish
Pages (from-to)371-379
Number of pages9
JournalClinical Microbiology and Infection
Volume17
Issue number3
DOIs
Publication statusPublished - Mar 2011

Fingerprint

Amoxicillin-Potassium Clavulanate Combination
Cefoxitin
Bacteroides fragilis
Clindamycin
Imipenem
Metronidazole
Ampicillin
Anti-Bacterial Agents
moxifloxacin
tigecycline
tazobactam drug combination piperacillin

Keywords

  • β-lactams
  • Antimicrobial resistance
  • Bacteroides fragilis group
  • Clindamycin
  • Metronidazole
  • Moxifloxacin
  • Tigecycline

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

@article{86362618a6f14ab8968bad5973b98b9d,
title = "Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe: 20years of experience",
abstract = "The susceptibilities of 824 Bacteroides fragilis group isolates against nine antibiotics were evaluated in a Europe-wide study involving 13 countries. Species determination, by different methods, was carried out on all but one isolate. Resistance rates were evaluated according to species and geographical areas via CLSI and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints. The present data were compared with those obtained 10 and 20years ago at a European level. High-level resistance (MIC ≥64mg/L) to ampicillin was observed in 44.5{\%} of the strains, which is a significant increase relative to 20years ago (16{\%}). Piperacillin/tazobactam was more active than amoxicillin/clavulanic acid (3.1{\%} and 10.4{\%} resistance, respectively), again with a resistance increase relative to earlier studies. Dramatic increases in resistance were observed for cefoxitin, clindamycin and moxifloxacin, with rates of 17.2{\%}, 32.4{\%} and 13.6{\%}, respectively. The lowest resistances were found for imipenem, metronidazole and tigecycline (1.2{\%},",
keywords = "β-lactams, Antimicrobial resistance, Bacteroides fragilis group, Clindamycin, Metronidazole, Moxifloxacin, Tigecycline",
author = "E. Nagy and E. Urb{\'a}n",
year = "2011",
month = "3",
doi = "10.1111/j.1469-0691.2010.03256.x",
language = "English",
volume = "17",
pages = "371--379",
journal = "Clinical Microbiology and Infection",
issn = "1198-743X",
publisher = "Elsevier Limited",
number = "3",

}

TY - JOUR

T1 - Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe

T2 - 20years of experience

AU - Nagy, E.

AU - Urbán, E.

PY - 2011/3

Y1 - 2011/3

N2 - The susceptibilities of 824 Bacteroides fragilis group isolates against nine antibiotics were evaluated in a Europe-wide study involving 13 countries. Species determination, by different methods, was carried out on all but one isolate. Resistance rates were evaluated according to species and geographical areas via CLSI and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints. The present data were compared with those obtained 10 and 20years ago at a European level. High-level resistance (MIC ≥64mg/L) to ampicillin was observed in 44.5% of the strains, which is a significant increase relative to 20years ago (16%). Piperacillin/tazobactam was more active than amoxicillin/clavulanic acid (3.1% and 10.4% resistance, respectively), again with a resistance increase relative to earlier studies. Dramatic increases in resistance were observed for cefoxitin, clindamycin and moxifloxacin, with rates of 17.2%, 32.4% and 13.6%, respectively. The lowest resistances were found for imipenem, metronidazole and tigecycline (1.2%,

AB - The susceptibilities of 824 Bacteroides fragilis group isolates against nine antibiotics were evaluated in a Europe-wide study involving 13 countries. Species determination, by different methods, was carried out on all but one isolate. Resistance rates were evaluated according to species and geographical areas via CLSI and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints. The present data were compared with those obtained 10 and 20years ago at a European level. High-level resistance (MIC ≥64mg/L) to ampicillin was observed in 44.5% of the strains, which is a significant increase relative to 20years ago (16%). Piperacillin/tazobactam was more active than amoxicillin/clavulanic acid (3.1% and 10.4% resistance, respectively), again with a resistance increase relative to earlier studies. Dramatic increases in resistance were observed for cefoxitin, clindamycin and moxifloxacin, with rates of 17.2%, 32.4% and 13.6%, respectively. The lowest resistances were found for imipenem, metronidazole and tigecycline (1.2%,

KW - β-lactams

KW - Antimicrobial resistance

KW - Bacteroides fragilis group

KW - Clindamycin

KW - Metronidazole

KW - Moxifloxacin

KW - Tigecycline

UR - http://www.scopus.com/inward/record.url?scp=79751518770&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79751518770&partnerID=8YFLogxK

U2 - 10.1111/j.1469-0691.2010.03256.x

DO - 10.1111/j.1469-0691.2010.03256.x

M3 - Article

VL - 17

SP - 371

EP - 379

JO - Clinical Microbiology and Infection

JF - Clinical Microbiology and Infection

SN - 1198-743X

IS - 3

ER -